Indian FMCG company selling personal care and healthcare brands including Boroplus, Navratna, Zandu and Fair and Handsome.
Indian FMCG company selling personal care and healthcare brands including Boroplus, Navratna, Zandu and Fair and Handsome.
Sells small-ticket everyday brands through a wide network of distributors and shops, with winter products like Boroplus and summer products like Navratna cooling oil and talc balancing the year. The Agarwal and Goenka families control it, and bought brands such as Zandu and Kesh King extended the range.
In one line: An Indian personal-care conglomerate, a smaller Unilever for skincare/ayurvedic brands.
Moat: narrow (brand, distribution). Strong rural distribution network and heritage brands in niche personal-care/ayurvedic categories.
Headquarters: Kolkata, India · Founded: 1974 · Employees: 5,447
Size Emami (EMAMILTD.NS) is an India Consumer Staples company (Household/Personal Care) with a market value of $1.94B, the 385th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹412.80 on 18 Nov 2026.
Performance Over six months the shares fell 5.1%, against +3.4% for the median peer and +3.8% for the India market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue grew 13.2% over the last twelve months (peer median +4.3%); the operating margin is 20.1% (peer median 9.9%).
Valuation It trades at 23.4× forward earnings against a peer median of 20.7× (9th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 21% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +16 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 9.4 points above its cost of capital (13.9% WACC).
Next results Next results expected around 14 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹42.0B | ₹37.8B | ₹38.1B | ₹35.8B | ₹34.1B |
| Revenue growth | — | -1% | +6% | +5% | — |
| Gross profit | ₹21.6B | ₹18.8B | ₹18.9B | ₹17.3B | ₹15.0B |
| EBITDA | ₹10.2B | ₹9.79B | ₹10.4B | ₹9.65B | ₹8.73B |
| Net income | ₹7.44B | ₹7.75B | ₹8.06B | ₹7.24B | ₹6.40B |
| Free cash flow | n/a | ₹7.64B | ₹8.60B | ₹7.42B | ₹7.11B |
| Capital expenditure | n/a | ₹433M | ₹446M | ₹406M | ₹405M |
| Total debt | ₹2.31B | ₹1.62B | ₹898M | ₹940M | ₹905M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Emami EMAMILTD.NS | $1.94B | -5% | +13% | 20% | 23.4× | 21.5% |
| Dabur India DABUR.NS | $7.16B | -16% | +9% | 15% | 31.8× | 27.4% |
| Hindustan Unilever HINDUNILVR.NS | $50.0B | -11% | +6% | 21% | 41.4× | 27.4% |
| Marico MARICO.NS | $12.6B | +9% | +20% | 16% | 52.2× | 28.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | EMAMILTD.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +10.1% | +0.9% | 3rd highest of 21 |
| 6-month return | -5.1% | +3.4% | 9th lowest of 21 |
| Distance from 52-week high | -25.1% | -24.2% | 10th lowest of 21 |
| Revenue growth (TTM) | +13.2% | +4.3% | 5th highest of 21 |
| Operating margin | 20.1% | 9.9% | 5th highest of 21 |
| Forward P/E | 23.4× | 20.7× | 9th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 21.5% | 0.5% | 2nd most demanding of 17 |
| Growth delivered (Del g) | +5.6% | +5.5% | 9th highest of 17 |
| Hurdle (Req g minus delivered) | +15.9 pp | -3.4 pp | 2nd most demanding of 17 |
| ROIC minus cost of capital | +9.4 pp | +5.1 pp | 5th highest of 20 |
| EV / EBITDA | 17.6× | 10.3× | 3rd most expensive of 14 |
| Net debt / EBITDA | -0.2× | -1.8× | 5th most indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Emami EMAMILTD.NS | India | $1.94B | -5% | +13% | 20% | 23.4× | 21.5% | +5.6% |
| Energizer ENR | United States | $1.94B | +71% | 0% | 17% | 9.1× | -5.1% | -0.5% |
| Pola Orbis 4927.T | Japan | $2.04B | +15% | +1% | 11% | 30.6× | -2.0% | -0.7% |
| Kolmar Korea 161890.KS | South Korea | $2.05B | +14% | +16% | 10% | 14.3× | -1.6% | +15.5% |
| Blue Moon 6993.HK | Hong Kong | $2.07B | -4% | -2% | -2% | 103.3× | n/a | n/a |
| Pigeon 7956.T | Japan | $1.76B | +26% | +8% | 13% | 27.9× | -2.4% | +1.9% |
| KOSE 4922.T | Japan | $2.16B | +16% | +4% | 5% | 29.9× | n/a | n/a |
| Softcare 2698.HK | Hong Kong | $2.20B | +5% | +25% | 25% | 14.4× | 9.1% | +20.9% |
| Yunnan Botanee Bio-Technology 300957.SZ | China | $1.69B | -33% | +7% | 9% | 19.1× | 2.6% | +15.3% |
| Guangdong Marubi Biotechnology 603983.SS | China | $1.62B | +9% | -6% | 2% | 45.5× | n/a | n/a |
| Shanghai Jahwa United 600315.SS | China | $1.61B | -15% | +9% | 2% | 15.4× | 15.3% | -2.1% |
| AMOREPACIFIC 002790.KS | South Korea | $1.61B | +2% | +9% | 9% | 8.5× | -5.7% | -1.3% |
| Procter & Gamble Hygiene & Health Care PGHH.NS | India | $2.37B | -30% | -2% | 24% | 27.0× | 21.2% | +7.4% |
| Giant Biogene 2367.HK | Hong Kong | $2.47B | -32% | -10% | 32% | 8.6× | -10.7% | +34.9% |
| Harbin Fuerjia Technology 301371.SZ | China | $1.51B | -39% | +28% | 20% | 21.4× | 7.5% | +3.6% |
| Cosmax 192820.KS | South Korea | $2.51B | +53% | +25% | 8% | 18.8× | n/a | n/a |
| Winner Medical 300888.SZ | China | $2.53B | -6% | +4% | 11% | 19.9× | -5.2% | -2.6% |
| Gillette India GILLETTE.NS | India | $2.53B | -5% | +8% | 28% | 37.1× | 14.9% | +13.0% |
| Intercos ICOS.MI | Italy | $1.43B | +12% | -5% | 9% | 18.9× | 4.3% | +11.5% |
| Chongqing Baiya Sanitary Products 003006.SZ | China | $1.35B | +27% | 0% | 3% | 37.3× | 28.8% | +22.8% |
| LG H&h 051900.KS | South Korea | $2.81B | -14% | -3% | 3% | 23.1× | -4.6% | -4.1% |